What is Interferon beta-1a SubQ injection?
Category: Prescription Drugs
Most popular types: Rebif Rebif Rebidose
Interferon beta-1a is an immunomodulator used to prevent episodes of symptoms and slow the development of disability in patients with relapsing-remitting multiple sclerosis. It comes as a solution to inject subcutaneously (under the skin) three times a week, ideally the same 3 days each week.
| Purpose | Patients | Evaluations | Perceived Effectiveness |
|---|---|---|---|
| Multiple sclerosis | 10753 | 1395 | |
| Stiffness/spasticity | 39 | 27 | |
| Fatigue | 28 | 5 | |
| General health | 18 | 12 | |
| Improve mobility | 9 | 4 | |
| Hepatitis C | 5 | 1 |
- Major
- Moderate
- Slight
- None
- Can't tell
Side effects
Side effects as an overall problem
| Severity | Evaluations | Percentage |
|---|---|---|
| Severe | 276 | |
| Moderate | 442 | |
| Mild | 502 | |
| None | 200 |
Commonly reported side effects and conditions associated with Interferon beta-1a SubQ injection
| Side effect | Patients | Percentage |
|---|---|---|
| Injection site redness | 181 | |
| Headaches | 164 | |
| Muscle aches | 161 | |
| Fever/chills | 138 | |
| Injection site pain | 110 | |
| Fatigue | 69 |
Why patients stopped taking Interferon beta-1a SubQ injection
Multiple reasons could be selected
| Reason | Patients | Percentage |
|---|---|---|
| Side effects too severe | 767 | |
| Did not seem to work | 536 | |
| Doctor's advice | 465 | |
| Other | 313 | |
| Expense | 83 | |
| Personal research | 71 | |
| Course of treatment ended | 33 | |
| Change in health plan coverage | 31 |
Duration
Stopped taking Interferon beta-1a SubQ injection
| Duration | Patients | Percentage |
|---|---|---|
| Less than 1 month | 93 | |
| 1 - 6 months | 312 | |
| 6 months - 1 year | 264 | |
| 1 - 2 years | 304 | |
| 2 - 5 years | 392 | |
| 5 - 10 years | 160 | |
| 10 years or more | 38 |
What people switch to and from
Patients started taking Interferon beta-1a SubQ injection after stopping:
| Treatment | Patients | Percentage |
|---|---|---|
| Glatiramer acetate (Copaxone) | 40 | |
| Interferon beta-1a IM Injection (Avonex) | 27 | |
| Interferon beta-1b SubQ Injection (Betaseron) | 12 | |
| Dimethyl fumarate (Tecfidera) | 9 | |
| Natalizumab (Tysabri) | 5 |
Patients stopped taking Interferon beta-1a SubQ injection and switched to:
| Treatment | Patients | Percentage |
|---|---|---|
| Dimethyl fumarate (Tecfidera) | 69 | |
| Glatiramer acetate (Copaxone) | 62 | |
| Natalizumab (Tysabri) | 54 | |
| Fingolimod (Gilenya) | 48 | |
| Teriflunomide (Aubagio) | 21 |
Last updated: